



Influenza (Flu)

Weekly U.S. Influenza Surveillance Report

FLUVIEW

A Weekly Influenza Surveillance Report Prepared by the Influenza Division



Key Updates for Week 44, ending November 2, 2019

According to this week's FluView report, seasonal influenza activity in the United States remains low but is increasing.

Viruses

Clinical Lab

3.2% of respiratory specimens tested by clinical laboratories were positive for influenza viruses. This is higher than the previous week.

Public Health Lab

Nationally, A(H3N2) and B/Victoria viruses have been most common; however, A(H1N1)pdm09 viruses also circulated. The predominant virus varies by region.

Virus Characterization


Data for this season will be reported when a sufficient number of viruses have been characterized. Virus characterization data through September 28 is [available](#).

Illness

Outpatient Illness: ILINet


2.1% of visits to a health care provider were for influenza-like illness (ILI). ILI activity is higher than the previous week but remains below the national baseline of 2.4%.

Outpatient Illness: ILI Activity Map



The majority of jurisdictions experienced minimal ILI activity; however, Louisiana and Puerto Rico experienced high ILI activity and 9 states experienced low ILI activity.

Geographic Spread



The majority of jurisdictions reported sporadic or local activity. Three states reported regional or widespread activity, and one state reported no activity.

Severe Disease

Hospitalizations

Data for this season will be provided when a sufficient number of hospitalizations have been reported.

P&I Mortality

Due to technical issues, data from the NCHS mortality surveillance system are not available this week.

Pediatric Deaths

No new influenza-associated pediatric deaths occurring during the 2019-2020 season were reported to CDC this week. The total for the season is 2.

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at <http://www.cdc.gov/flu/weekly/overview.htm>.

Additional information on the current and previous influenza seasons for each surveillance component are available on [FluView Interactive](#)

Key Messages from CDC

- Nationally, flu activity is low and similar to what has been observed during recent previous seasons at the same time, but Louisiana and Puerto Rico both continue to experience high levels of influenza-like-illness.
- It's too early to characterize the timing of the season, what viruses will predominate, or how severe the season will be.
- Flu vaccination is always the best way to prevent flu and its potentially serious complications. Most flu vaccines protect against 4 different flu viruses. Get vaccinated now.

U.S. Virologic Surveillance


Clinical Laboratories

The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

	Week 44	Data Cumulative since September 29, 2019 (week 40)
No. of specimens tested*	18,126	101,524
No. of positive specimens (%)	582 (3.2%)	1,978 (1.9%)
<i>Positive specimens by type</i>		
Influenza A	143 (24.6%)	738 (37.3%)
Influenza B	439 (75.4%)	1,240 (62.7%)

* The total number of specimens tested by clinical laboratories decreased this week for this season because one high volume laboratory has been removed due to questions about testing practices and data interpretation.

The majority (63%) of all influenza viruses and 75% of the influenza B viruses reported by clinical laboratories thus far this season were from the south and southeast regions (regions 4 and 6).




[View Chart Data](#) | [View Full Screen](#)

Public Health Laboratories

The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.

	Week 44	Data Cumulative since September 29, 2019 (week 40)
No. of specimens tested	766	5,022
No. of positive specimens	117	873
<i>Positive specimens by type/subtype</i>		
Influenza A	54 (46.2%)	491 (56.2%)
(H1N1)pdm09	22 (41.5%)	153 (34.8%)
H3N2	31 (58.5%)	287 (65.2%)
Subtyping not performed	1	51
Influenza B	63 (53.8%)	382 (43.8%)
Yamagata lineage	4 (9.5%)	11 (3.7%)
Victoria lineage	38 (90.5%)	287 (96.3%)

Nationally, influenza A(H3N2) and B/Victoria viruses have been reported more frequently than other influenza viruses this season; however, influenza A(H1N1)pdm09 viruses are also circulating widely. The predominant virus varies by region. For regional and state level data about circulating influenza viruses, please visit [FluView Interactive](#).



For additional virologic surveillance information for this season and past seasons: [Surveillance Methods](#) | [FluView Interactive: National, Regional, and State Data](#) or [Age Data](#)

Influenza Virus Characterization


CDC performs [genetic](#) and [antigenic](#) characterization of U.S. viruses submitted from state and local health laboratories using Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses used for developing new influenza vaccines and to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

Virus characterization data will be updated starting later this season when sufficient numbers of specimens have been tested.

Outpatient Illness Surveillance

ILINet

Nationwide during week 44, 2.1% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.4%.



[View Chart Data](#) | [View Full Screen](#)

On a regional level, the percentage of outpatient visits for ILI ranged from 1.2% to 3.8% during week 44. Region 6 (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas) and Region 7 (Iowa, Kansas, Missouri, and Nebraska) reported a percentage of outpatient visits for ILI which is equal to their region-specific baselines. All other regions remained below their region-specific baselines.

ILI Activity Map

Data collected in ILINet are used to produce a measure of **ILI activity*** by state.

During week 44, the following ILI activity levels were experienced:

- High – Puerto Rico and one state (Louisiana) (Louisiana)
- Low – nine states (Alabama, Arkansas, Colorado, Georgia, Hawaii, Missouri, South Carolina, Texas, and Virginia)
- Minimal – the U.S. Virgin Islands, the District of Columbia, New York City, and 40 states (Alaska, Arizona, California, Connecticut, Delaware, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming)


A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINet

prev Play Pause next

40 41 42 43 44

weeks
2019-20 Influenza Season Week 44 ending Nov 02, 2019



Season: 2019-20

Download Data Download Data

*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

Additional information about medically attended visits for ILI this season and past seasons:
[Surveillance Methods](#) | [FluView Interactive: National, Regional, and State Data](#) or [ILI Activity Map](#)

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses but does not measure the severity of influenza activity.

During week 44 the following influenza activity was reported:

- Widespread – two states (Louisiana and Maryland)
- Regional – one state (Alabama)
- Local – Puerto Rico and 15 states (Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Mississippi, Nevada, New Hampshire, South Carolina, Tennessee, Texas and West Virginia).
- Sporadic – the District of Columbia, the U.S. Virgin Islands and 31 states (Alaska, Arkansas, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Maine, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming).
- No activity – one state (Rhode Island)
- Guam did not report.

A Weekly Influenza Surveillance Report Prepared by the Influenza Division
Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

<<40 Play Pause >>

41

42


43

44

Weeks

Week Ending Nov 02, 2019 - Week 44

Influenza Activity Estimates



Season: 2019-20

Download Image Download Data

Most Recent Flu Activity data in XML Format (<https://www.cdc.gov/flu/weekly/flureport.xml>) | View Full Screen (<http://gis.cdc.gov/grasp/fluview/FluView8.html>)

***This map indicates geographic spread and does not measure the severity of influenza activity.**

Additional information about the geographic spread of influenza this season and past seasons:
[Surveillance Methods](#) | [FluView Interactive](#)

Influenza-Associated Hospitalizations

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in the Emerging Infections Program (EIP) states and Influenza Hospitalization Surveillance Project (IHSP) states. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season when a sufficient number of hospitalizations have been reported.

Additional FluSurv-NET data can be found at: <http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html> and <http://gis.cdc.gov/grasp/fluview/FluHospChars.html>.

Pneumonia and Influenza (P&I) Mortality Surveillance


Due to technical issues, the National Center for Health Statistics (NCHS) mortality surveillance data for the week ending October 26, 2019 (week 43) will not be published this week. Reporting of this data will resume once the technical issues have been resolved.

Additional pneumonia and influenza mortality surveillance information for current and past seasons:
[Surveillance Methods](#) | [FluView Interactive](#)

Influenza-Associated Pediatric Mortality

No influenza-associated pediatric deaths were reported to CDC during week 44.

A total of two influenza-associated pediatric deaths occurring during the 2019-2020 season have been reported to CDC.



[View Full Screen](#)

Additional Influenza-associated pediatric mortality surveillance information for current and past seasons:
[Surveillance Methods](#) | [FluView Interactive](#)

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit <http://www.cdc.gov/flu/weekly/fluviewinteractive.htm>

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH at <https://www.cdc.gov/niosh/topics/absences/default.html>

U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information

Alabama	Alaska	Arizona	Arkansas	California
Colorado	Connecticut	Delaware	District of Columbia	Florida
Georgia	Hawaii	Idaho	Illinois	Indiana
Iowa	Kansas	Kentucky	Louisiana	Maine
Maryland	Massachusetts	Michigan	Minnesota	Mississippi
Missouri	Montana	Nebraska	Nevada	New Hampshire
New Jersey	New Mexico	New York	North Carolina	North Dakota
Ohio	Oklahoma	Oregon	Pennsylvania	Rhode Island
South Carolina	South Dakota	Tennessee	Texas	Utah
Vermont	Virginia	Washington	West Virginia	Wisconsin
Wyoming	New York City	Puerto Rico	Virgin Islands	

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through [FluNet](#) and the [Global Epidemiology Reports](#).

WHO Collaborating Centers for Influenza located in [Australia](#), [China](#), [Japan](#), the [United Kingdom](#), and the [United States](#) (CDC in Atlanta, Georgia).

Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European Centre for Disease Prevention and Control at <http://www.flunewseurope.org/>.

Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at <http://www.phac-aspc.gc.ca/fluwatch/>

Public Health England: The most up-to-date influenza information from the United Kingdom is available at <https://www.gov.uk/government/statistics/weekly-national-flu-reports>

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at: <http://www.cdc.gov/flu/weekly/overview.htm>.

Page last reviewed: November 8, 2019

Content source: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)